Drugs / AK129
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05645276 | Mar 2023 → Feb 2026 overdue | high grade malignant neoplasm | Akeso | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06943820 | May 2025 → Dec 2026 expected | colorectal adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06642792 | Jan 2025 → Nov 2027 expected | classic Hodgkin lymphoma | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06586294 | Sep 2024 → Jul 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Akeso | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06642792 ↗ |
| Action | Inhibit | “block the interaction of PD-1/programmed cell death - ligand 1(PD-L1), LAG-3/ major histo-compatibility complex II(MHCII)” NCT05645276 ↗ |
| Route | Intravenous | “administered intravenously” NCT05645276 ↗ |